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Background/Objective: Tumor necrosis factor-a (TNF-a) antagonists have become increasingly popular in
the treatment of psoriasis. However, the increased risk of latent tuberculosis infection (LTBI) reactivation
has also become an important issue in clinical practice. The aim of this study was to evaluate serial
QuantiFERON-TB Gold In-Tube (QFT-GIT) testing for detecting LTBI among a cohort of psoriatic patients
vaccinated with bacille Calmette-Guerin in a country with an intermediate burden of TB during long-
term treatment with TNF-a antagonists.
Methods: We enrolled psoriatic patients treated with TNF-a antagonists who also accepted yearly serial
QFT-GIT testing and regular chest X-ray examinations before and during the anti-TNF-a treatment from
January 2010 to August 2014. Patients diagnosed with LTBI received chemoprophylaxis, and QFT-GIT
testing was performed in these patients after completion of chemoprophylaxis.
Results: In this retrospective study, 101 patients had completed baseline and at least 1 year of follow-up.
Among these patients, 60 had continued TNF-a antagonists therapy and received examinations in the
2nd year, whereas 18 had continued the therapy until the 3rd year. The conversion rate among these
patients was 14.29% (13/91). In this study, 23 patients were diagnosed with LTBI according to the
positive results obtained in the QFT-GIT test, with 19 of them having completed chemoprophylactic
therapy. Follow-up QFT-GIT testing revealed reversion in 11 patients (57.89%) and decreased interferon-g
(IFN-g) levels (68.42%) in 13 patients. Patients over 45 years of age tended to have a persistent positive
result.
Conclusion: This study demonstrated that 14.29% of psoriatic patients undergoing long-term TNF-a
antagonist therapy had a QFT-GIT conversion. Although a decreased IFN-g level and QFT-GIT reversion
were observed in most cases following prophylactic therapy, the value of QFT-GIT for evaluating the
effect of LTBI prophylaxis remains controversial.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
The use of tumor necrosis factor-a (TNF-a) antagonists in psoriatic
patients has become more common in recent years. However,y have no ﬁnancial or non-
atter or materials discussed
logy, Chang Gung Memorial
05, Taiwan.
ng).
cal Association. Published by Elsevpatients treated with TNF-a antagonists are at increased risk of
latent tuberculosis infection (LTBI) reactivation; therefore,
screening for LTBI prior to initiating TNF-a antagonist therapy is
important.1,2 The tuberculin skin test (TST) is considered one of the
standard methods of screening for TB infection. However, TST has
some disadvantages. For example, false-positive results may occur
in patients previously vaccinated with bacille Calmette-Guerin
(BCG), which may limit its usefulness in high BCG-vaccinated
populations.3 In addition, TST is not speciﬁc for Mycobacterium
tuberculosis infection, and cross reactivity with environmental
mycobacteria may occur.4 TST may also overestimate LTBI risk inier Taiwan LLC. All rights reserved.
Table 1 Summary of the demographic data, clinical characteristics, and treatment in
our series (101 cases).
Age (y) 43.41 ± 11.33
Sex Women: 32 (31.7)
Men: 69 (68.3)
Patients with psoriatic arthritis 59 (58.4)
BCG vaccine 95 (95)
PASI score 14.87 ± 8.71
Treatment with TNF-a inhibitor Etanercept: 89 (88.1)
Adalimumab: 12 (11.9)
Combined treatment MTX: 22 (21.8)
Cyclosporine: 9 (8.9)
Acitretin: 11 (10.9)
Prednisolone: 1 (1)
Data are presented as n (%) or mean ± SD.
BCG¼ bacille Calmette-Guerin; MTX¼methotrexate; PASI¼ Psoriasis Area Severity
Index (0e72); QFT-GIT ¼ QuantiFERON-TB Gold In-Tube; SD ¼ standard deviation;
TNF ¼ tumor necrosis factor.
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cause koebnerization, which interferes with the evaluation of TST.5
Recently, whole-blood interferon-g release assays (IGRAs) were
introduced for the diagnosis of LTBI, including the QuantiFERON-TB
Gold In-Tube test (QFT-GIT; Cellestis Limited, Carnegie, Victoria,
Australia) and T-SPOT TB test (Oxford Immunotec, Oxford, UK). In
contrast to TST, IGRA is more speciﬁc for screening LTBI and is not
affected by BCG vaccination.6 Therefore, IGRA is considered supe-
rior to TST for detecting LTBI in countries with an intermediate to
high burden of TB as well as in countries with high BCG vaccination
rates.
Although there are many studies discussing a test to screen for
LTBI in patients with psoriasis who have not started receiving TNF-
a antagonist therapy, the long-term follow-up of LTBI in such
patients is limited. The aim of this study was to evaluate the QFT-
GIT test for detecting LTBI in a cohort of BCG-vaccinated patients
with moderate-to-severe psoriasis, receiving long-term treatment
with TNF-a antagonists in a country with an intermediate burden
of TB.
Materials and methods
Patients
In this retrospective study, we enrolled psoriatic patients treated
with TNF-a antagonists from January 2010 to August 2014 at Chang
Gung Memorial Hospital, Linkou, Taiwan. All the patients had
accepted to receive yearly serial IGRA testing and regular chest X-
ray examinations before and during the anti-TNF-a treatment. All
patients received at least one 12-week course of TNF-a antagonist
therapy, including either etanercept or adalimumab. The medical
records of these patients were reviewed to evaluate demographic
information, clinical diagnosis, medication history, and laboratory
data.
QuantiFERON-TB Gold In-Tube assay for latent tuberculosis
infection
All the patients underwent serial testingwith QFT-GIT for screening
of LTBI. The antigens used in QFT-GIT are a peptide cocktail simu-
lating the proteins ESAT-6, CFP-10, and TB7.7. The interferon-g (IFN-
g) values were calculated by subtracting the value obtained with nil
antigens, with a cutoff value of 0.35 IU/mL. A positive result was
deﬁned as an IFN-g of nil antigens < 8.0 IU/mL and an IFN-g
response of  25% of nil antigens. A negative result was deﬁned as
an IFN-g of nil antigens < 8.0 IU/mL and an IFN-g response of < 25%
of nil antigens or an IFN-g response minus nil antigens < 0.35 IU/
mL. Results with an IFN-g of nil antigens > 8.0 IU/mL or IFN-g of
mitogen minus nil antigens < 0.5 U/mL were interpreted as inde-
terminate. Conversion of IGRA was deﬁned as a negative IGRA at
baseline and a positive IGRA at follow-up, and reversion of IGRA
was deﬁned as a positive IGRA at baseline and negative IGRA at
follow-up.
Treatment and follow-up of LTBI
In this study, the diagnosis of LTBI was made on the basis of a
positive QFT-GIT result and a negative chest radiograph or micro-
biological assay. Patients diagnosed with LTBI were referred to a
pulmonologist and received chemoprophylactic therapy. During
the course of chemoprophylactic therapy, all the patients under-
went regular laboratory investigation of liver enzymes and bili-
rubin level. A follow-up QFT-GIT test was performed in these
patients following completion of the chemoprophylactic therapy.Statistical analysis
SPSS version 17 (SPSS Inc., Chicago, IL, USA) was used for all the
analysis in this study. The Wilcoxon signed-rank test was used to
compare the IFN-g level before and after the prophylactic therapy.
A comparison of patients with a persistent positive result and
reversion of QFT-GIT after completion of chemoprophylaxis for LTBI
was performed using the Fisher's exact test for categorical data.
Results
Patient characteristics
In total, 101 patients were enrolled in this study. Of these patients,
69 were men (68.3%) and the median age was 41 years
(43.41 ± 11.33 years). Ninety-ﬁve patients received BCG vaccination
(95%), 89 patients received etanercept (88.1%), and 12 patients
received adalimumab (11.9%). Thirty-one patients also received
concomitant immunosuppressant therapy during the anti-TNF-a
treatment. Among these patients, methotrexate was the most
commonly used drug (21.8%), and two patients were treated with
more than one immunosuppressant. According to chest radio-
graphs, none of the patients had a previous history of TB or active
pulmonary lesions. The demographic data are presented in Table 1.
Outcome of serial IGRA
The patient distribution, according to the QFT-GIT status, at base-
line and at follow-up, of active treatment is summarized in the
study ﬂowchart (Figure 1). In this series, all of the 101 patients
completed evaluations at baseline and at least 1 year of follow-up.
Among these patients, 60 (59.41%) had continued both TNF-a
antagonist therapy and received examinations into the 2nd year,
whereas 18 (17.82%) had continued the therapy into the 3rd year.
The median cumulative durations of TNF-a antagonist therapy
were 33 (31.98 ± 11.89) weeks, 26 (26.38 ± 11.74) weeks, and 26
(29.44 ± 10.12) weeks during the 1st year, 2nd year, and 3rd year of
follow-up, respectively. The initial IGRA result was positive in 10
patients (9.9%), negative in 85 patients (84.2%), and indeterminate
in six patients (5.9%). The serial QFT-GIT results are demonstrated
in Figure 2. The conversion rate was 14.29% (13/91) in the serial
QFT-GIT tests. Ten patients had QFT-GIT conversion following their
second tests, whereas others had QFT-GIT conversion following
their third test. All the initial indeterminate results were negative
following the second QFT-GIT test, whereas two patients with
initial negative results had indeterminate results at the second and
third tests. No active TB infection was noted in our series.
Figure 1 Flowchart distribution of QuantiFERON Gold In-Tube (QFT-GIT) test results.
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In this study, 23 patients were diagnosed with LTBI according to the
positive results obtained in the QFT-GIT test. With the exception of
two patients who refused to receive prophylactic therapy due to
personal reasons, all the others received prophylactic therapy. Two
patients developed elevated liver enzymes following a regular
laboratory investigation and hence, only received a 4-month course
of prophylactic therapy with 300 mg of daily isoniazid (INH). In
total, 19 patients had completed the whole course of prophylactic
therapy (Table 2). Among these patients, 10 (52.63%) received a 9-
month course of INH therapy, whereas three cases (15.79%)
received a 6-month course of INH therapy. Four patients had
initially received INH and then shifted to a 4-month course ofrifampicin (RIF) therapy (600 mg/d) because of elevated liver en-
zymes, hepatotoxicity, or allergy to INH. In addition, two cases had
a previous history of peripheral neuropathy; therefore, they
received a 4-month course of RIF therapy to avoid possible INH
neurotoxicity. In our series, these patients received the QFT-GIT test
within 1e6months of completing the prophylactic therapy. Follow-
up QFT-GIT testing revealed reversion in 11 patients (57.89%) and
decreased IFN-g levels (68.42%) in 13 patients. The longitudinal
change in IFN-g level is shown in Figure 3. There was no signiﬁcant
change in the level of IFN-g before and after chemoprophylaxis
(p ¼ 0.22). Moreover, when comparing the persistent positive and
reversion groups (Table 3), no signiﬁcant differences were observed
in either sex, anti-TB regimen, IFN-g level at ﬁrst result, the time
that LTBI had been diagnosed, or the type of TNF-a antagonist used.
Figure 2 Results of serial QuantiFERON-TB Gold In-Tube (QFT-GIT) tests.
Figure 3 Interferon-g (IFN-g) response toMycobacterium tuberculosis-speciﬁc antigens
measured before and after chemoprophylaxis.
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have a persistent positive result (p ¼ 0.02). Interestingly, one pa-
tient who had not received prophylactic therapy and two patients
who only received a 4-month course of INH treatment due to
elevated liver enzymes also had reversion following subsequent
QFT-GIT tests.Discussion
In recent years, TNF-a antagonists have become increasingly pop-
ular in the treatment of psoriasis and other rheumatoid diseases
although the increased risk of LTBI reactivation has also now
become an important issue in clinical practice. Taiwan is a country
with an intermediate burden of TB with an annual incidence of 57/
100,000 and mortality rate of 2.8/100,000. According to Matulis
et al,7 those living in countries with a high prevalence of TB had a
higher risk of developing LTBI. Therefore, screening for LTBI beforeTable 2 Treatment and follow-up of LTBI patients.
Case Sex Age BCG vaccine TNF-a antagonists Anti-TB Anti-TB
(mo)
1 M 56 Y Enbrel INH 9
2 M 60 N Enbrel INH/RIF 1.5 þ 4a
3 F 38 Y Enbrel INH 6
4 M 57 Y Enbrel INH/RIF 2 þ 4b
5 M 41 Y Enbrel INH 9
6 M 57 Y Enbrel INH 9
7 M 65 Y Enbrel INH 6
8 M 38 Y Humira INH 9
9 M 31 Y Enbrel INH 9
10 M 35 Y Enbrel INH 6
11 M 54 Y Enbrel INH/RIF 0.5 þ 4a
12 M 40 Y Enbrel INH 9
13 M 32 Y Enbrel INH 9
14 M 39 Y Enbrel INH 9
15 F 49 Y Enbrel INH 9
16 F 25 Y Enbrel INH/RIF 2 þ 4c
17 M 54 Y Enbrel RIF 4
18 F 46 Y Enbrel RIF 4
19 F 48 Y Enbrel INH 9
A ¼ adalinumab; AST ¼ aspartate aminotransferase; ALT ¼ alanine transaminase; BC
LTBI ¼ latent tuberculosis infection; QFT-GIT ¼ QuantiFERON-TB Gold In-Tube; RIF ¼ rifa
a Patient 2 and Patient 11 changed LTBI prophylaxis from INH to RIF due to elevated l
b Patient 4 changed LTBI prophylaxis from INH to RIF due to acute hepatitis (AST: 237
c Patient 16 changed LTBI prophylaxis from INH to RIF due to allergy to INH.and during the treatment with TNF-a antagonists is essential to
prevent adverse effects of the medication and control an infectious
disease. According to previous studies, the mechanisms by which
TNF-a antagonists interfere with anti-TB immunity may be related
to blocking TNF-mediated immune responses, inhibiting phag-
olysosomal maturation, inducing monocyte apoptosis, and
reducing IFN-g secretion by memory T cells.8 Among the TNF-a
antagonists, patients treated with adalimumab had a greater risk of
developing TB than those treated with etanercept.9 The median
time of developing TB in patients treated with adalimumab and
etanercept were 3e8 months and 11.2 months, respectively.10,11
Therefore, the recommended interval of screening for LTBI during
the TNF-a antagonist therapy was at least 12 months.
TB screening is recommended prior to initiating TNF-a antago-
nist therapy and at yearly intervals, thereafter.12 TB infection
screening should include detailed medical history, chest X-ray, and
either TST or IGRA tests. The medical history should include TB
infection risk factors such as residence in a country with a burden of
TB, travel to endemic areas, substance abuse, or health careduration IFN-g level (IU/mL) before
chemoprophylaxis
IFN-g level (IU/mL)
after chemoprophylaxis
Reversion
0.37 0.89 N
0.52 0.9 N
2.37 1.85 N
0.73 3.83 N
0.42 0.08 Y
2.98 0.13 Y
0.49 0.26 Y
0.57 0.03 Y
1.03 0.08 Y
3.77 0.01 Y
1.15 0.04 Y
0.47 0.12 Y
0.46 0.04 Y
0.54 0.29 Y
1.17 1.28 N
1.27 0.18 Y
2.31 3.39 N
1.52 2.73 N
0.52 0.35 N
G ¼ bacille Calmette-Guerin; E ¼ etanercept; IFN ¼ interferon; INH ¼ isoniazid;
mpicin; TB ¼ tuberculosis; TNF ¼ tumor necrosis factor; TST ¼ tuberculin skin test.
iver enzyme level.
IU/mL and ALT: 486 IU/mL).
Table 3 Comparison of persistent positive result and reversion of QFT-GIT in pa-
tients who were treated with chemoprophylaxis.
Persistent positive
group (N ¼ 8)
Reversion group
(N ¼ 11)
p
Age (y) 0.02 *
> 45 7 3
 45 1 8
Sex 0.111
Male 4 10
Female 4 1
Anti-TB therapy 0.171
INH 4 9
INH/RIF 2 2
RIF 2 0
TNF regimen > 0.99
Etanercept 8 10
Adalimumab 0 1
IFN-g level at ﬁrst positive result (IU/mL) > 0.99
> 1 4 6
 1 4 5
Diagnosis of LTBI 0.170
Initial examination 6 2
Subsequent examination 4 7
* Signiﬁcant at p < 0.05.
IFN ¼ interferon; INH ¼ isoniazid; LTBI ¼ latent tuberculosis infection; QFT-
GIT ¼ QuantiFERON-TB Gold In-Tube; RIF ¼ rifampicin; TB ¼ tuberculosis;
TNF ¼ tumor necrosis factor.
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TB.12 In addition, it is necessary to ascertain whether the patient
had any symptoms related to TB infection, including cough, loss of
body weight, night sweats, and fever. Currently, TST and IGRA are
the two available methods for detection of LTBI. Although some
studies showed consistent results between the two tests, systemic
review and meta-analysis showed that the speciﬁcity of IGRAs was
superior to TST.11 The odds ratio for positive TST results in patients
who received BCG vaccination varied from three to 25, whereas
IGRAwas not inﬂuenced by BCG vaccination.6 Taiwan launched the
neonatal BCG vaccination program in 1965, and the coverage rate
was above 97% after 2001.13 The coverage rate (95%) of BCG vacci-
nations in our series was similar to the nationwide data; therefore,
IGRA is more speciﬁc and suitable for detection of LTBI in this study.
A number of previous studies have demonstrated higher per-
centages of indeterminate QFT-GIT results in the immunocompro-
mised rather than in the immunocompetent patients (21.4% vs.
9.6%, p ¼ 0.021).14 However, in this study, indeterminate results at
baseline examination were only found for six patients (5.9%) in
agreement with Chiu et al,15 who also described a low rate of
indeterminate results.15 These ﬁndings may be associated with the
relatively low percentage of patients receiving other immunosup-
pressive agents. In comparison with other serial IGRA for moni-
toring LTBI in patients who received TNF-a antagonists, the
conversion rate in our series was 14.29%, which is similar to the
ﬁndings of other studies in Korea (12.1%) and in Italy (11.6%) where
the TB burden was intermediate and low, respectively.16,17 The
conversion of QFT-GIT may be attributed to new TB infection, cross
reactivity with other species of Mycobacterium, or laboratory bias.
Indeed, few patients also had a change in QFT-GIT status between
indeterminate and negative results and reversion without pro-
phylactic therapy. These ﬁndings are similar to previous studies,
which demonstrated that patients who received long-term biologic
therapy experienced dynamic changes in the IFN-g level in
response to TB.18,19
Currently, there are several therapies available for LTBI,
including either a 9- or 6-month course of INH, a 4-month course
of RIF, or a 3-month course of INH plus RIF. Most of our patients
diagnosed with LTBI received chemoprophylaxis. Among thesepatients, ﬁve of 19 patients (26.31%) who received prophylactic
INH therapy had elevated liver enzymes, whereas two dis-
continued the chemoprophylaxis. Three also shifted to RIF ther-
apy as hepatotoxicity was less common in patients receiving RIF
than in those receiving INH.20 After chemoprophylactic therapy,
the IFN-g level decreased in 13 (68.42%) patients, whereas 11
(57.89%) patients developed reversion in the subsequent QFT-GIT
test. The reversion rate in patients who received INHP in the
present study was higher than that (30.54%) in a meta-analysis
that estimated the pooled percentage of reversion after 3e6
months of follow-up.21 In addition, the reversion rate in our
study was also higher than that in the study of Sauzullo et al19
who demonstrated only an 8% reversion rate in psoriatic pa-
tients receiving TNF-a antagonist following INHP for LTBI. The
difference may be related to different LTBI prophylactic regimens
or the time points of testing with QFT-GIT. Although the higher
rate of reversion and decreased level of IFN-g were demonstrated
in our study, no signiﬁcant change in the IFN-g level before and
after chemoprophylaxis was observed. In the study by Johnson
et al,22 there was also no signiﬁcant difference in the IFN-g level
decline between the INHP group and the observation group. In
comparison, among patients with persistently elevated IFN-g
levels and reversion following chemoprophylaxis, we found
those aged less than 45 years were more likely to have IGRA
reversion. This result is similar to the study of Bartalesi et al23
who demonstrated that patients who were older, had larger
TST size, or a higher baseline level of IFN-g were less likely to
achieve reversion, although no signiﬁcant correlation of baseline
IFN-g level and reversion occurred in our series. Bartalesi et al23
suggested that TB infection in younger patients is more likely to
have occurred recently without remote infection, with these
patients tending to achieve lower levels of IFN-g following
treatment. However, the present study did not show a signiﬁcant
association between reversion rate and the time that LTBI has
been diagnosed. Therefore, the actual mechanism is still unclear.
In conclusion, this study has described the long-term follow-up
of psoriatic patients receiving TNF-a antagonist therapy. We found
that 14.29% of psoriatic patients who had undergone long-term
TNF-a antagonist therapy had QFT-GIT conversion. No active TB
infection had been noted in our series. Although decreased IFN-g
levels and QFT-GIT reversion were observed in most patients
following chemoprophylaxis, the value of QFT-GIT for evaluating
the effect of LTBI prophylaxis remains controversial. Thus, the
current screening and management of LTBI may be effective in
patients receiving TNF-a antagonists therapy. However, a larger,
controlled prospective study is warranted before QFT-GIT is intro-
duced for clinical practice in the long-term screening of psoriatic
patients receiving TNF-aantagonist therapy.
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